Latest Posts



Jun 24

Partex and Singapore’s Experimental Drug Development Centre collaborate to bring forward an innovative approach for early drug discovery and development

Frankfurt, Germany, 3rd June 2024, 9am CET Partex, a leading provider of AI-driven solutions in the pharmaceutical industry, is thrilled...
Read More


Apr 24

Partex Partners with Lupin to Revolutionize Drug Discovery through AI-Driven Asset Search and Evaluation

Frankfurt, Germany, 23 April 2024 – Partex, a leading provider of AI-driven solutions in the pharmaceutical industry, is thrilled to...
Read More

Innoplexus wins Horizon Interactive Gold Award for Curia App

Read More

The virtual summit on the use of AI technology in Oncology

Event Date: Wed, 28 Jan 2021
Event Location: Dubai

The AI in Oncology Summit will be focusing on the practical application and potential use of Artificial Intelligence (AI) in the therapeutic area of oncology. AI can provide a competitive edge by preserving and enhancing the value of the R&D pipeline through AI-based approaches. The summit will be held in a digital format and will explore how companies could improve their clinical development performance even in times of unprecedented challenges related to COVID-19.



Juergen Scheele
SMD Senior Medical Director

Prof. Dr. Dr. Juergen Scheele is the Global Clinical Development Lead for Tepotinib at Merck KGaA.


Andreas Penk
Adv. Board, CancerCoin

Dr. Andreas Penk is a member of the Advisory Board of CancerCoin


Oliver Eckelmann
CEO, Discoveric Bio

Oliver Eckelmann, PhD is an entrepreneur that is leading and involved in the founding of several Biotech companies.


Gunjan Bhardwaj
CEO, Innoplexus

Dr. Gunjan Bhardwaj is the Chief Executive Officer of the German Artificial Intelligence company Innoplexus AG.

Date, Schedule & Speakers

January 28, 2021, at 4 pm to 5.30 pm

Time Topic Speaker
16:00 – 16:10 Introduction
Greetings and a short summary of the story of and the tech behind Innoplexus
Gunjan Bhardwaj, Innoplexus
16:10 – 16:30 Challenges in oncology drug development
Learn more about how to handle opportunities and challenges in oncology drug development using a strategic approach
Juergen Scheele, Merck
16:30 – 16:50 Revolutionizing drug discovery with AI-powered target identification
Find out how the Discoveric Bio Group augments their team of researchers with AI-driven analytics
Oliver Eckelmann, Discoveric Bio Group
16:50 – 17:10 Accelerating oncology research with blockchain
CancerCoin is a new concept of using blockchain to improve the ability to bring oncology drugs safer to the market
Andreas Penk, CancerCoin
17:10 – 17:30 Summary & closing remarks
Wrap up of the summit and some sneak peeks on what next developments will happen in AI-powered oncology research
Gunjan Bhardwaj, Innoplexus